From GlobeNewswire: 2024-06-04 16:10:00

Abivax SA, a biotechnology company, held its general meeting of shareholders on May 30, 2024, chaired by CEO Marc de Garidel. Shareholders approved all resolutions proposed by the Board, including financial statements for 2023 and appointment of new Board members. Details on vote results can be found on the company’s website. Abivax’s lead drug candidate, Obefazimod, demonstrated positive data in Phase 2 trials for Ulcerative Colitis and is now in a pivotal global Phase 3 clinical trial. Phase 2b trials for Crohn’s disease are expected in Q3 2024, and exploration of combination therapy opportunities is ongoing. For more information, visit www.abivax.com.



Read more at GlobeNewswire: Abivax releases the results of its May 30, 2024 Ordinary